Breakthrough clinical trials into new treatments for bone marrow and liver cancer will soon commence after experienced institutional biotech investors with positive track records in companies such as Viralytics, Ophthea and Avita committed $7.2 million towards funding the trials for Pharmaxis (ASX: PXS) and their hero drug PXS-5505. Unlike other cancer treatment drugs on the
Read More
Promising early study results released today by clinical stage drug development company Pharmaxis (ASX: PXS), should be a reason for investors to stir. Pharmaxis’ latest clinical trial (MF-101) focuses on bone marrow cancer myelofibrosis and potential treatment with their hero drug, PXS-5505. Having already proven the drug’s tolerability and efficacy in terms of absorption, distribution,
Read More
Streamlining operations to focus on the most profitable side of their pharmaceuticals manufacturing business, Pharmaxis (ASX: PXS) has shored up its cash position via the sale of distribution rights in Russia for their cystic fibrosis treatment which is gathering international momentum. The deal will send exclusive distribution rights in Russia to specialty company GEN İlaç
Read More
In biotech circles, tackling a rare and difficult disease with few patients does not necessarily equate to targeting an unprofitable one. In the case of fibrotic diseases specialist Pharmaxis (ASX: PXS), its proposed treatment for the rare blood cancer myelofibrosis presents a potential billion dollar-plus market, even though only about 15 in every 1 million
Read More